Advertisement

Innovative Antimetabolites in Solid Tumours

  • Matti S. Aapro
Conference proceedings

Part of the ESO Monographs book series (ESO MONOGRAPHS)

Table of contents

  1. Front Matter
    Pages i-vii
  2. Matti S. Aapro
    Pages 1-1
  3. Gilbert B. Zulian
    Pages 3-9
  4. Kurt Possinger, James Carmichael, Philip Phillip, Maria Beykirch, Helen Kerr, Jackie Walling et al.
    Pages 33-35
  5. Jan P. Neijt, Birthe Lund
    Pages 37-41
  6. Maurizio Tonato, Anna Maria Mosconi
    Pages 53-59

About these proceedings

Introduction

The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.

Keywords

Antimetabolit Antimetabolite Antimetabolites Cladribin Onkologie breast cancer cancer cancer treatment cell chemotherapy fludarabine lung cancer oncology ovarian cancer tumor

Editors and affiliations

  • Matti S. Aapro
    • 1
    • 2
  1. 1.Divisione di Oncologia MedicaIstituto Europeo di OncologiaMilanoItaly
  2. 2.Division d’Onco-HématologieHôpital Cantonal UniversitaireGenève 14Switzerland

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-79200-7
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-79202-1
  • Online ISBN 978-3-642-79200-7
  • Buy this book on publisher's site